Gibson Dunn Advises Fairmount Funds on $110 Million PIPE Transaction for Inhibikase Therapeutics
Firm News | October 9, 2024
Gibson, Dunn & Crutcher LLP advised Fairmount Funds on its participation in the $110 million PIPE transaction for Inhibikase Therapeutics.
The Gibson Dunn corporate team was led by partners Branden Berns and Ryan Murr.